Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

INTRODUCTION: Haemophilia A is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. This is treated with factor VIII, conventionally using products with a half-life of 8–12 hours typically administered every 2–3 days. Recombinant FVIII Fc (rFVIIIFc) represents a new generat...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldenburg, Johannes, Hay, Charles R M, Jiménez-Yuste, Víctor, Peyvandi, Flora, Schved, Jean-François, Szamosi, Johan, Winding, Bent, Lethagen, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549707/
https://www.ncbi.nlm.nih.gov/pubmed/31152037
http://dx.doi.org/10.1136/bmjopen-2018-028012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549707/
https://www.ncbi.nlm.nih.gov/pubmed/31152037
http://dx.doi.org/10.1136/bmjopen-2018-028012

Ejemplares similares